Implantable cardiac devices, such as pacemakers, are used to treat a number of heart conditions, especially those related to the electrical conduction system. Cardiac pacemakers are a well-established and effective therapy, and have been in use for more than 50 years.
In addition to their treatment capability, there are a number of algorithms available for today's implantable cardiac devices that allow them to also be used as diagnostic tools. For example, detection of transthoracic impedance has been used to measure respiratory efforts for many years. In addition, for more than a decade many pacemakers have included integrated respiratory minute volume sensors as part of a basic algorithm to adapt the heart rate. 4 Recently, this capability was enhanced to allow detection of cardiac decompensations by measuring changes in intrathoracic fluids. 5 A growing number of implantable cardiac devices also now have the ability to detect SDB. [6] [7] [8] 
Sleep-disordered Breathing
Interest in SDB among cardiologists is increasing rapidly due to the high prevalence of SDB in patients with cardiovascular disease.
The prevalence of SDB in cardiovascular patients is particularly high in those with cardiac dysrhythmias and heart failure (HF; see Figure 1 ). excessive daytime sleepiness. 10, 11 CSA is characterised by repetitive cessation of ventilation during sleep resulting from a loss of ventilatory drive. A central apnoea is a 10-second pause in ventilation with no associated respiratory effort. CSA is present when a patient has five or more central apnoeas or hypopnoeas per hour.
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Implantable Cardiac Electronic Devices and SDB Diagnosis
The ability of current implantable cardiac devices (pacemakers, ICDs and CRT) to determine transthoracic impedance, and therefore detect and quantify breathing efforts, makes them capable of detecting SDB.
Multichannel polysomnography (PSG) is the gold standard tool for the detection and quantification of SDB. 13 However, PSG is costly and needs to be undertaken at specialist clinics. As a result, alternative, less expensive and more convenient options that can offer good reliability are becoming increasingly attractive, particularly for the detection and monitoring of SDB in cardiac patients and for monitoring the effects of therapy.
Thoracic impedance is determined by the relation of air to fluids between the measurement locations. Implantable pacemakers measure transthoracic impedance between an endocardial implanted lead and the pectoral aggregate. Thoracic impedance rises with inspirational efforts and falls during expiration. 4 Implantable cardiac devices have been used to detect SDB for at least a decade, and their ability to do so has been validated in comparisons with multichannel polysomnography (PSG) recordings, the gold standard for diagnosing SDB. 7, 8, [14] [15] [16] [17] [18] [19] [20] Recently, the internal SDB detection algorithm of an implanted pacemaker device documented a high prevalence of SDB (up to 75 %) in a cohort of 32 unselected cardiac patients. 21 SDB definition varies between different devices. The algorithm of a pacemaker by Sorin (Paris, France) records an apnoea when there is breathing cessation of >10 seconds, and a hypopnoea when the breathing amplitude is reduced by ≥50 % for >10 seconds; the number of events per hour is used to calculate the respiratory disturbance index (RDI). 22 In devices from Boston Scientific (St. Paul, Minnesota, USA), the SDB detection algorithm also registers apnoeas as breathing cessation of >10 seconds, but hypopnoeas as a ≥26 % decrease in transthoracic impedance amplitude for >10 seconds and the AHI is calculated as a reflection of the RDI. The algorithms of devices from both companies have been validated against multichannel PSG, with the Sorin algorithm in Talent™-3 pacemakers (ELA Medical, Montrouge, France) identifying severe SDB with sensitivity of 75 % and specificity of 94 %. 22 In another study utilising Boston Scientific (Guidant) pacemakers, there was a good correlation between the calculated RDI and the AHI measured using PSG (r = 0.8), with sensitivity of 82 % and specificity of 88 % for detecting severe SDB. In addition, ability to continuously monitor SDB means that patient monitoring can be improved, with the possibility of detecting deterioration early and therefore initiating appropriate changes in therapy.
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Implantable Cardiac Electronic Devices and SDB Therapy
Patients with relevant SDB and symptomatic HF need to be treated with optimal medical therapy according to current local guidelines. When left ventricular function is severely impaired (≤35 %) and in the presence of left bundle branch block, CRT implantation is indicated. 28 In addition to beneficial cardiovascular effects, CRT implantation has been shown to also be associated with a significant improvement in and New York Heart Association functional class (p<0.0001).
35-37 AHI was reduced, but not to normal levels, and there was no data on the effects of therapy on cardiac performance and patient prognosis.
There is also an implantable device available for patients with OSA.
This stimulates the hypoglossus nerve to prevent upper airway collapse. Implantation of the electrodes for this device is more complex and requires surgery on the neck because direct access and preparation of the nerve are necessary. Furthermore, video endoscopic sleep examination is mandatory to identify appropriate candidates for this procedure. As such, this device has limited clinical application 38 but the first clinical data are promising. Over 12 months with a response to therapy were then included in a randomised, controlled trial of therapy withdrawal, which showed a rebound increase in the AHI when upper airway stimulation was withdrawn (to 25.8 per hour from 7.6 per hour, p<0.001). The rate of procedurerelated serious adverse events was <2 %. 40 
Conclusions, Outlook and Clinical Perspective
SDB is a highly prevalent comorbidity in patients with cardiac dysrhythmia, HF and in those with implanted cardiac devices.
Today's pacemaker, ICD or CRT devices have the ability to constantly monitor transthoracic impedance making them capable of detecting and quantifying SDB. Results from the first studies of new devices are promising and they reveal the potential of this technology.
Detected SDB events and severity show good correlation with PSG, the gold standard for diagnosing SDB. The latest implantable device technology even allows treatment of SDB, via selective stimulation of the hypoglossus nerve for OSA and via phrenic nerve stimulation for CSA. Clinical studies are underway to determine the usefulness of the latter approach for the treatment of CSA and the suppression of CSR. One of the benefits of the new phrenic nerve stimulation device is that it is inserted using a well-known transvenous implantation procedure.
The main limitation of the new implantable devices is that they do not record oximetry or sleep and breathing parameters. Nevertheless, the ability of implantable cardiac devices to detect SDB could have clinical utility, not only for SDB screening but also to monitor SDB severity and document the effectiveness of SDB treatment. Implantable devices are also able to measure additional parameters, including intrathoracic fluids, heart rate variability, and activity parameters. This type of information may allow early detection of worsening of HF and facilitate the prevention of clinical events. There are currently no randomised, controlled clinical trials looking at this utility, but this is an area for future research. n
